| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_chr6_0218000 | Intergenic-Intergenic | chr6:146274804-146275043 | chr6:145953668-145953907 | 240 nt | 0.2875 |
| hsa_SHPRH_0014400 | Exon-Exon | chr6:146275826-146275989 | chr6:145954690-145954853 | 164 nt | 0.3720 |
| hsa_chr6_0218100 | Intergenic-Intergenic | chr6:146275886-146276257 | chr6:145954750-145955121 | 372 nt | 0.3575 |
| hsa_SHPRH_0014600 | Intron-Intron | chr6:146281177-146281482 | chr6:145960041-145960346 | 306 nt | 0.4020 |
A review of literature indicates that the circSHPRH is a tumor suppressor in brain cancer, specifically glioblastoma, where it is downregulated and its encoded SHPRH-146aa peptide inhibits glioma growth [Di Agostino et al. DOI:10.3389/fcell.2020.00389]. A review of human studies indicates that the circSHPRH is downregulated in colorectal cancer tissues and is associated with metastasis and survival, while its overexpression inhibits proliferation and cell cycle progression [Lee et al. DOI:10.1016/j.biopha.2018.12.052].